Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
Paolo Lopedote,1 Mazyar Shadman2,3 1Department of Medicine, St Elizabeth’s Medical Center, Boston, MA, USA; 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3Department of Medicine, University of Washington, Seattle, WA, USACorrespondence: Mazyar Shadman, Clinical Resear...
Main Authors: | Lopedote P, Shadman M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-03-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/targeted-treatment-of-relapsed-or-refractory-follicular-lymphoma-focus-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma
by: Javier Sanchez Alvarez, et al.
Published: (2023-10-01) -
Treatment selection for patients with relapsed or refractory follicular lymphoma
by: Alan Z. Skarbnik, et al.
Published: (2023-03-01) -
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
by: Ollila TA, et al.
Published: (2021-05-01) -
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
by: Zhijuan Lin, et al.
Published: (2023-04-01) -
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)